San Diego-based mostly Viking Therapeutics marked alone as a significant competitor from the weight loss drug market in February following revealing promising facts from a mid-phase demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March the comp